Perjeta, Herceptin, Avastin, Kadcyla, Rituxan Treanda and Abraxane patients: Provis fully particpates in the Treanda, Abraxane and Roche Patient Support Program. For qualified Perjeta, Herceptin, Avastin, Kadcyla, Rituxan, Abraxane and Treanda patient financial assistance maybe available. Please contact Provis for further information.
Why Choose Provis?
- Infusion Services Since 2005
- Over 11,000+ Infusions To Date
- Most Comprehensive Oncology Drug Formulary in Canada
- Onsite Medication Compounding Facility
- Experienced Pharmacists On-Site
- Experienced Oncology Trained Nurses
- Supervising Physician On-Site
12 Year Anniversary!The Provis Infusion Clinic is please to announce that August 2017 marks the 12 anniversary of the Provis Infusion Clinic. We are looking forward to the next 12 years of providing high quality infusion services.
Sunnybrook Health Sciences Centre PartnershipProvis has been chosen as the preferred provider by Sunnybrook Health Sciences Centre for private paid infusions originating from the hospital. For further details please contact Provis.
Expanded Indications for OPDIVO™ and KEYTRUDA™OPDIVO™ is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving OPDIVO™. KEYTRUDA™ has received NOC with Conditions for use in the treatment of patients with: Metastatic NSCLC whose tumours express PD-L1 and who have a disease progression on or after platinum-containing chemotherapy. patients with EGFR or ALK genomic tumour aberrations should have disease progression on authorized therapy for these aberrations prior to receiving KEYTRUDA™.
Kyprolis™ (Carfilzomib) receives Health Canada approval.Health Canada has approved Kyprolis™ (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
Opdivo™ (Nivolumab) receives Health Canada approval.Opdivo™ is the first anti PD-1 (programmed death-1) approved to treat previously untreated cases of BRAF V600 wild-type unresectable or metastatic melanoma in adults. The approval was made under the Health Canada Priority Review process, after having met the criteria of substantial evidence of clinical effectiveness providing an improved benefit/risk profile over existing therapies. Provis is also able to provide Opdivo™ for other indications if required.
Keytruda™ (Pembrolizumab) now offered at ProvisAUTHORIZATION WITH CONDITIONS OF KEYTRUDA™ for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor
Update – Patient Support Programs
Keytruda®, Perjeta®, Herceptin®, Avastin®,Jevtana®, Rituxan®, Abraxane®, Treanda® Kadcyla® and Kyprolis® Patients: Provis participates in the Roche Patient Assistance Program, the Treanda Support Program, the Merck Care Oncology, Kyprolis (Victory) and Celgene Abraxane® Access Program . These program offers financial assistance to qualified patients receiving Kyprolis®, Keytruda®, Perjeta®, Herceptin®, Avastin®, Rituxan®, Abraxane®,Treanda® and Kadcyla® Read More >>
Non-Muscle Invasive Bladder CancerProvis works with the University Urology Associates (UUA), in providing the compounded MMC for electronically stimulated Mitomycin-C (EMDA MMC) to treat non-muscle invasive bladder cancer.
The Ride to Conquer CancerThe Provis Pelotons Cycling Team participate in the 2015 Ride to Conquer Cancer. The ride is over 220km's from Toronto to Niagara Falls. The team raised close to $13,000 for cancer research. Way to go Graham, Deb, Steve, Samantha and Dave.